Neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma.
10.3760/cma.j.cn441530-20221214-00526
- Author:
Rui CHEN
1
;
Jian Hua FU
1
Author Information
1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer, Medicine , Guangzhou 510060, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Esophageal Squamous Cell Carcinoma/surgery*;
Neoadjuvant Therapy;
Esophageal Neoplasms/surgery*;
Chemoradiotherapy;
Esophagectomy
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(4):312-318
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of surgery alone for locally advanced esophageal squamous cell carcinoma (ESCC) is limited. In-depth studies concerning combined therapy for ESCC have been carried out worldwide, especially the neoadjuvant treatment model, including neoadjuvant chemotherapy (nCT), neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy combined with immunotherapy (nICT), neoadjuvant chemoradiotherapy combined with immunotherapy (nICRT), etc. With the advent of the immunity era, nICT and nICRT have attracted much attention from researchers. An attempt was thus made to take an overview of the evidence-based research advance regarding the neoadjuvant therapy of ESCC.
